Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis

PURPOSE: A population pharmacokinetic model was developed for nintedanib in patients with non-small cell lung cancer (NSCLC) or idiopathic pulmonary fibrosis (IPF). The effects of intrinsic and extrinsic patient factors on exposure of nintedanib and its main metabolite BIBF 1202 were studied. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmid, Ulrike, Liesenfeld, Karl-Heinz, Fleury, Angele, Dallinger, Claudia, Freiwald, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754397/
https://www.ncbi.nlm.nih.gov/pubmed/29119292
http://dx.doi.org/10.1007/s00280-017-3452-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754397/
https://www.ncbi.nlm.nih.gov/pubmed/29119292
http://dx.doi.org/10.1007/s00280-017-3452-0

Ejemplares similares